

## Grape Seed Proanthocyanidins Protect Cardiomyocytes From Ischemia and Reperfusion Injury Via Akt-NOS Signaling

Zuo-Hui Shao,<sup>1</sup> Kimberly R. Wojcik,<sup>1,2</sup> Anar Dossumbekova,<sup>1</sup> Chinwang Hsu,<sup>3</sup> Sangeeta R. Mehendale,<sup>4</sup> Chang-Qing Li,<sup>1</sup> Yimin Qin,<sup>1,2</sup> Willard W. Sharp,<sup>1</sup> Wei-Tien Chang,<sup>5</sup> Kimm J. Hamann,<sup>1,2</sup> Chun-Su Yuan,<sup>4</sup> and Terry L. Vanden Hoek<sup>1\*</sup>

<sup>1</sup>Department of Medicine, Emergency Resuscitation Center, Section of Emergency Medicine, University of Chicago, Chicago, Illinois 60637

<sup>2</sup>Department of Medicine, Section of Pulmonary and Critical Care Medicine, University of Chicago, Chicago, Illinois 60637

<sup>3</sup>Tri-service General Hospital, National Defense Medical Center, Taiwan, ROC

<sup>4</sup>Department of Medicine, Tang Center for Herbal Medicine Research, Section of Anesthesia & Critical Care, University of Chicago, Chicago, Illinois 60637

<sup>5</sup>Department of Emergency Medicine, National Taiwan University Hospital and National Taiwan, University College of Medicine, Taiwan, ROC

### ABSTRACT

Ischemia/reperfusion (I/R) injury in cardiomyocytes is related to excess reactive oxygen species (ROS) generation and can be modulated by nitric oxide (NO). We have previously shown that grape seed proanthocyanidin extract (GSPE), a naturally occurring antioxidant, decreased ROS and may potentially stimulate NO production. In this study, we investigated whether GSPE administration at reperfusion was associated with cardioprotection and enhanced NO production in a cardiomyocyte I/R model. GSPE attenuated I/R-induced cell death [ $18.0 \pm 1.8\%$  (GSPE, 50  $\mu\text{g/ml}$ ) vs.  $42.3 \pm 3.0\%$  (I/R control),  $P < 0.001$ ], restored contractility (6/6 vs. 0/6, respectively), and increased NO release. The NO synthase (NOS) inhibitor N $\omega$ -nitro-L-arginine methyl ester (L-NAME, 200  $\mu\text{M}$ ) significantly reduced GSPE-induced NO release and its associated cardioprotection [ $32.7 \pm 2.7\%$  (GSPE + L-NAME) vs.  $18.0 \pm 1.8\%$  (GSPE alone),  $P < 0.01$ ]. To determine whether GSPE induced NO production was mediated by the Akt-eNOS pathway, we utilized the Akt inhibitor API-2. API-2 (10  $\mu\text{M}$ ) abrogated GSPE-induced protection [ $44.3\% \pm 2.2\%$  (GSPE + API-2) vs.  $27.0\% \pm 4.3\%$  (GSPE alone),  $P < 0.01$ ], attenuated the enhanced phosphorylation of Akt at Ser473 in GSPE-treated cells and attenuated GSPE-induced NO increases. Simultaneously blocking NOS activation (L-NAME) and Akt (API-2) resulted in decreased NO levels similar to using each inhibitor independently. These data suggest that in the context of GSPE stimulation, Akt may help activate eNOS, leading to protective levels of NO. GSPE offers an alternative approach to therapeutic cardioprotection against I/R injury and may offer unique opportunities to improve cardiovascular health by enhancing NO production and increasing Akt-eNOS signaling. *J. Cell. Biochem.* 107: 697–705, 2009. © 2009 Wiley-Liss, Inc.

**KEY WORDS:** GRAPE SEED PROANTHOCYANIDIN EXTRACT; ISCHEMIA/REPERFUSION INJURY; CARDIOMYOCYTES; NITRIC OXIDE; Akt

The use of antioxidants to reduce oxidant injury during reperfusion is postulated to improve cardiac recovery from ischemia. Research in this field continues to explore various modalities and chemical entities that may attenuate oxidant activity

at reperfusion and consequently reduce cardiac reperfusion injury [Ambrosio et al., 1995; Zweier and Talukder, 2006; Bolli, 2007]. Antioxidant compounds, which could be administered at reperfusion to mitigate tissue oxidant load, are now being considered as

Dr. Chun-Su Yuan and Dr. Terry L. Vanden Hoek contributed equally to this work.

Grant sponsor: National Institutes of Health; Grant numbers: HL68951, HL65558, HL79641, HL084643, AT003255, AT01575, AT002176.

\*Correspondence to: Terry L. Vanden Hoek, MD, Department of Medicine, Section of Emergency Medicine, The University of Chicago, 5841 S. Maryland Avenue, MC 5068, Chicago, IL 60637.

E-mail: thoek@medicine.bsd.uchicago.edu

Received 23 January 2009; Accepted 11 March 2009 • DOI 10.1002/jcb.22170 • © 2009 Wiley-Liss, Inc.

Published online 22 April 2009 in Wiley InterScience (www.interscience.wiley.com).

potential therapeutic interventions [Sato et al., 1999; Das and Maulik, 2006; Chang et al., 2007]. In that context, several herb-derived compounds that are extremely potent antioxidants [Rice-Evans, 2001] could be protective against acute oxidant stress. Grape seed proanthocyanidin extract (GSPE) is a mixture of several flavonoid constituents with potent antioxidant activity [Hung et al., 2000; Bagchi et al., 2003; Karthikeyan et al., 2007], and the consumption of grape skin- and grape seed-derived products has been linked to reduced incidence of cardiovascular disease [Das and Maulik, 2006].

In addition to the ability to scavenge reactive oxygen species (ROS) [Rice-Evans, 2004], GSPE has the ability to stimulate other cardioprotective pathways. Our previous work has shown that GSPE stimulates NO production in untreated cardiomyocytes in a dose-dependent manner. High-dose GSPE induced a high level of NO production that was associated with increased cardiomyocyte death while lower doses of GSPE were associated with a moderate increase in NO generation and did not induce cytotoxicity [Shao et al., 2006]. NO, which is a relatively stable free radical, acts as a signaling molecule in diverse physiological and pathological pathways. Recent studies indicate that augmenting NO bioavailability in acute oxidant stress models such as ischemia/reperfusion (I/R) is protective [Bolli, 2001; Schulz et al., 2004; Jones and Bolli, 2006]. Furthermore, the protective effect of polyphenolic antioxidants such as resveratrol in models of I/R has been attributed to increased NO production, as the nitric oxide synthase (NOS) inhibitor *N* $\omega$ -nitro-L-arginine methyl ester (L-NAME) abrogates their protective effects [Bradamante et al., 2003; Thirunavukkarasu et al., 2007]. Thus, as an antioxidant that has the ability to stimulate NO release, GSPE may be a unique candidate for imparting protection against I/R injury.

NO release in numerous cellular models including cardiomyocytes has been intrinsically linked to regulation of NOS by the cell survival kinase Akt. Currently it is unknown if GSPE activates Akt, but several other antioxidants have been shown to confer improved cellular function via Akt activation [Toth et al., 2003; Goh et al., 2007]. In addition, the protective effect of resveratrol in a rat model of I/R has been shown, in part, to be due to activation of Akt [Goh et al., 2007]. It is therefore possible that GSPE induction of NO may occur via activation of the Akt-eNOS pathway [Hattori et al., 2002; Wallerath et al., 2002; Ha et al., 2008].

In the current study, we have investigated the effect of GSPE on both NO production and Akt activation in an acute oxidant stress model of ischemia and reperfusion. We hypothesized that acute GSPE treatment would confer protection from I/R injury to cardiomyocytes and that this protection would be due, at least in part, to the activation of Akt, leading to an increased production of NO during reperfusion.

## MATERIALS AND METHODS

### MATERIALS

Grape seed proanthocyanidin extract (GSPE), a water-alcohol extract from red grape seeds, was kindly provided by Prof. C.S. Yuan (Tang Center for Herbal Medicine Research, University of Chicago).

The components of GSPE were analyzed using high liquid chromatography (HPLC) with gas chromatography (GC)-mass spectrometry (MS) by Adpen Laboratories, Inc. (Jacksonville, FL). The results of chemical analysis showed that GSPE is comprised of oligomeric proanthocyanidins (approximately 62.3%), monomeric flavanols (8.6% catechin, 8.7% epicatechin), and gallic acid (2.7%). API-2 (Akt/protein kinase B signaling inhibitor-2) was kindly provided by Prof. J.Q. Cheng (H. Lee Moffitt Cancer Center & research Institute, FL, USA). *N* $\omega$ -nitro-L-arginine methyl ester (L-NAME) was purchased from Sigma (St. Louis, MO).

### METHODS

**Chick primary cardiomyocyte culture.** Embryonic chick ventricular myocytes were isolated as previously described [Vanden Hoek et al., 1996]. Briefly, hearts of 10-day-old chick embryos were removed; the ventricles were minced and enzymatically digested with 0.025% trypsin (Invitrogen, Grand Island, NY) for 4–5 cycles with gentle agitation at 37°C. The resultant cell suspension was centrifuged, and the cell pellet was resuspended in media. Fibroblast contamination was reduced by pre-plating the cells for 45 min, and the purity of cardiomyocytes was confirmed as previously described [Vanden Hoek et al., 1996]. Cells ( $0.7 \times 10^6$ ) were plated onto glass coverslips (25 mm) and cultured in a humidified incubator for 3 days at which point the cells demonstrate synchronous contractions. Experiments were performed on day 4 or 5 using spontaneously contracting cells.

**Simulated ischemia/reperfusion protocol.** Synchronously contracting cells on glass coverslips were placed in a stainless steel flow-through chamber (1.2 ml volume, Penn Century Co., Philadelphia). The chamber was sealed with gaskets to minimize any O<sub>2</sub> exchange and mounted on an inverted microscope. The flow rate (0.25 ml/min), pH, temperature (37°C), and oxygen tension of the perfusate were controlled throughout the experiment. The standard perfusate for equilibration and reperfusion consisted of a buffered salt solution with a PO<sub>2</sub> of 149 torr, PCO<sub>2</sub> of 40 torr, pH of 7.4, 4.0 mM [K<sup>+</sup>], and 5.6 mM glucose. Simulated ischemic perfusate consisted of a buffered salt solution with 20 mM 2-deoxyglucose, 8.0 mM [K<sup>+</sup>], and no glucose. The ischemic solution was bubbled with 80% N<sub>2</sub> and 20% CO<sub>2</sub> to produce a PO<sub>2</sub> < 3 torr, PCO<sub>2</sub> of 144 torr, and a final pH of 6.8. We used an optical method of phosphorescence quenching (Oxyspot, Medical Systems, Inc., Greenvale, NY) to verify the conditions of ischemia [Vanden Hoek et al., 1997]. GSPE (50 μg/ml) was given throughout reperfusion in all applicable studies.

**Video/fluorescent microscope.** A Nikon TE 2000-U inverted phase/epifluorescent microscope was used for cell imaging. A charged-coupled device camera was used to monitor contractions and measure fluorescence over time in the same field of cells (approximately 70 μm × 90 μm). Fluorescent images were acquired from a cooled Cool-SNAP-ES camera (Photometrics, Tucson, AZ) and changes in fluorescent intensity over time were quantified with MetaMorph<sup>®</sup> software (Molecular Devices Corp., Downingtown, PA) [Vanden Hoek et al., 1997].

**Viability assay and contraction analysis.** Cell viability was assessed by the fluorochrome propidium iodide (PI, 5 μM; Sigma) at

excitation 540 nm/emission 590 nm. PI is a fluorescent exclusion dye that binds to chromatin upon loss of cell membrane integrity. Cell death was quantified throughout the experiment in a select field of cells. At the end of each experiment, all cells in this field were permeabilized with digitonin (300  $\mu$ M). Percentage cell death (PI uptake) was expressed as PI fluorescence relative to the maximal value seen after 1 h of digitonin exposure (100%). Cell contractions were assessed as previously reported [Vanden Hoek et al., 1996]. A return of contraction was indicated when contractions were seen throughout the field of cells.

**Measurement of intracellular nitric oxide (NO) generation.** Intracellular NO production was measured using the fluorescent dye 4, 5-diaminofluorescein diacetate (DAF-2 DA, 1  $\mu$ M; EMD Biosciences, Inc., San Diego, CA). DAF-2 DA is a specific NO indicator that can penetrate rapidly into the cell, where it is hydrolyzed to DAF-2 by intracellular esterases. DAF-2 selectively traps NO, yielding fluorescent triazolofluorescein, which is measured at excitation 488 nm/emission 520 nm. Measurements were expressed as arbitrary units (a.u.) [Kojima et al., 1998].

**Western blot analysis for Akt activation.** Cardiomyocytes were subjected to experimental conditions and lysed at designated time points in cold lysis buffer (1% Triton-X100, 50 mM Tris pH 7.5, 40 mM  $\beta$ -glycerophosphate, 100 mM NaCl, 2 mM EDTA, 50 mM NaF, 200  $\mu$ M  $\text{Na}_3\text{VO}_4$ , and 200  $\mu$ M PMSF). Bradford assays (BioRad, Hercules, CA) were performed to determine protein concentration. Proteins (50  $\mu$ g) were then separated on 10% SDS-PAGE gels (BioRad) and transferred to nitrocellulose (0.45  $\mu$ m, Osmonics, Westborough, MA). Blots were blocked in 5% milk TBS-T for 1 h at room temperature followed by an overnight incubation at 4°C with primary antibody (Akt or phospho-Akt at Ser473; Cell Signaling) in 5% BSA TBS-T. Blots were then washed in several changes of TBS-T followed by 1 h incubation with the appropriate HRP-conjugated secondary antibody. Blots were washed as above and bands were

visualized using SuperSignal West Femto Maximum Sensitivity Substrate (Pierce). Densitometric analysis of Western blots was carried out using Quantity One Software (Bio-Rad, Richmond, CA), and results are presented as the ratio of phospho-Akt:total Akt.

## DATA ANALYSIS

Each individual experiment on a field of  $\sim$ 500 cells represented an "n" of 1. All data are expressed as mean  $\pm$  SEM. Statistical analysis was performed using commercially available statistic software (Sigma Stat 3.0). Data between groups recorded over an interval were compared using a two-way repeated measures ANOVA. When significant, Tukey's post-hoc test was performed for comparison between individual groups. A *P*-value <0.05 was considered statistically significant.

## RESULTS

### GSPE PROTECTS CARDIOMYOCYTES FROM ISCHEMIA/ REPERFUSION (I/R) INJURY

To test whether GSPE protects cardiomyocytes against I/R-induced injury, cells were subjected to I/R and treated with GSPE during reperfusion. Cell death was assessed by propidium iodide (PI) uptake. We have previously reported that GSPE given at 50  $\mu$ g/ml conferred optimal protection against oxidant-induced injury in cardiomyocytes [Shao et al., 2003], thus, this dose was used in the current study. As seen in Figure 1, GSPE (50  $\mu$ g/ml) given at reperfusion (arrow) resulted in a significant decrease in cell death compared to I/R control [18.0  $\pm$  1.8% vs. 42.3  $\pm$  3.0% at 3 h reperfusion, respectively (n = 6/group, *P* < 0.01 to *P* < 0.001)]. Cell contractions also returned in GSPE-treated cells (6/6), but not in control I/R cells (0/6). These results indicate that GSPE treatment produced a profound and significant protection against I/R-induced cell death.




Fig. 1. Effect of GSPE on I/R-induced cell death. GSPE (50  $\mu$ g/ml) given during reperfusion significantly attenuated cell death in cardiomyocytes. Data are expressed as means  $\pm$  SEM, n = 6/group. #*P* < 0.01, \**P* < 0.001 compared to I/R control cells.

## THE ROLE OF NITRIC OXIDE (NO) IN GSPE-CONFERRED PROTECTION AGAINST I/R INJURY

NO has been postulated to play a protective role against cardiac I/R injury. As an NO indicator, DAF-2 DA has proven to be useful in detecting rapid NO generation in cardiomyocytes [Lebuffe et al., 2003]. We tested whether NO production, as measured by DAF-2 fluorescence, was increased with GSPE given during reperfusion and whether the increased NO release was associated with GSPE-conferred protection. Cells were loaded with DAF-2 DA (1  $\mu$ M) and treated with GSPE (50  $\mu$ g/ml). As seen in Figure 2A, GSPE-treated cells showed a marked increase in DAF-2 fluorescence during reperfusion as compared to I/R control cells [ $1,839 \pm 49$  a.u. vs.  $810 \pm 76$  a.u. at 2 h reperfusion ( $n = 4/\text{group}$ ,  $P < 0.01$ )]. To determine if the GSPE-induced increase in NO was generated

through NOS, cardiomyocytes were pre-incubated with L-NAME (200  $\mu$ M) for 2 h and continuously throughout the entire I/R protocol. This NOS inhibition partially abrogated the enhanced DAF-2 fluorescence seen in GSPE-treated cells ( $n = 4$ ,  $P < 0.05$ ), but had no effect on control I/R NO generation (Fig. 2A). Blocking NOS activation with L-NAME also at least partially abrogated the GSPE-mediated reduction in cell death [ $32.7\% \pm 2.7\%$  GSPE + L-NAME vs.  $18.0\% \pm 1.8\%$  GSPE only at 3 h reperfusion ( $n = 6/\text{group}$ ,  $P < 0.01$ ); Fig. 2B], but did not significantly affect control I/R cell death [ $40.2\% \pm 4.5\%$  L-NAME ( $n = 7$ ) vs.  $42.3\% \pm 2.9\%$  I/R control at 3 h reperfusion ( $n = 4$ , NS; Fig. 2B)]. These results suggest that the enhanced NO production at reperfusion is associated with GSPE-protection and may be mediated by enzymatic NOS.




Fig. 2. Effect of NOS inhibition on GSPE-induced NO production and protection. Cells were pretreated with L-NAME (200  $\mu$ M) for 2 h and also throughout the I/R protocol. GSPE (50  $\mu$ g/ml) was administered only during reperfusion. A: Effect of NOS inhibition (L-NAME) on DAF-2 fluorescence in GSPE-treated cells subjected to I/R. DAF-2 fluorescence was significantly increased at the end of 30 min reperfusion in I/R control. GSPE (50  $\mu$ g/ml) given at reperfusion further augmented the DAF-2 fluorescence, resulting in a twofold increase compared to I/R cells. Data are expressed as means  $\pm$  SEM,  $n = 4/\text{group}$ ;  $^{\#}P < 0.01$ . L-NAME (200  $\mu$ M) concurrent with GSPE (50  $\mu$ g/ml) treatment partially reversed the increased DAF-2 fluorescence seen in GSPE-treated cells ( $n = 4/\text{group}$ ,  $^{\dagger}P < 0.05$ ). B: Effect of L-NAME on the protective effect in GSPE-treated I/R cells. L-NAME partially abrogated the GSPE-induced cardioprotection. Data are expressed as means  $\pm$  SEM,  $n = 6/\text{group}$ .  $^{\#}P < 0.01$  versus GSPE-treated cells.

### ROLE OF Akt IN GSPE-INDUCED NO PRODUCTION

Recent studies have shown that cardioprotection is associated with NO production following Akt-mediated eNOS activation in cardiomyocytes [Gao et al., 2002; Li et al., 2008]. Therefore, since we showed that NO generation is increased during GSPE-induced protection, we examined whether Akt was involved in the sustained reperfusion NO induced by GSPE. Cardiomyocytes were loaded with DAF-2 DA and treated with the Akt inhibitor API-2 (10  $\mu$ M, 1 h pretreatment and throughout I/R). NO generation was measured in the presence and absence of GSPE (50  $\mu$ g/ml, given at reperfusion). Figure 3A shows that blocking Akt activation partially abrogated the GSPE-induced increase in DAF-2 fluorescence [1,241  $\pm$  60 a.u. GSPE + API-2 (n=3) vs. 1,803  $\pm$  97 a.u. GSPE alone (n=3) at 2 h reperfusion,  $P < 0.05$ ], implying that Akt plays a role in mediating GSPE-induced NO production in the context of I/R injury.

### ROLE OF Akt IN GSPE-INDUCED CARDIOPROTECTION

Activation of Akt has been linked to protection against I/R injury in several cell types and animal models [Toth et al., 2003; Goh et al., 2007; Roviezzo et al., 2007]. To further examine the involvement of Akt in the protection conferred by GSPE, the effect of API-2 (10  $\mu$ M) on cell death was examined. Figure 3B shows that inhibition of Akt abrogated GSPE-induced protection [44.3  $\pm$  2.2% GSPE + API-2 (n=4) vs. 28.0  $\pm$  2.3% GSPE alone (n=5) at 3 h reperfusion,  $P < 0.01$ ]. However, Akt inhibition did not have a significant effect on control I/R cell death [48.3  $\pm$  5.1% I/R + API-2 (n=5) vs. 52.8  $\pm$  5.8% I/R control at 3 h reperfusion (n=5), NS].

Western blot analyses showed a drop in phospho-Akt during ischemia and I/R, but GSPE (50  $\mu$ g/ml) given during reperfusion significantly increased phospho-Akt at Ser473 as compared to I/R control (n=3,  $P < 0.01$ , Fig. 4). The Akt inhibitor API-2 blocked the




Fig. 3. Effect of Akt inhibition on GSPE-induced NO production and protection. Cells were pretreated with the Akt inhibitor API-2 (10  $\mu$ M) for 1 h and also throughout the course of the experiment. GSPE (50  $\mu$ g/ml) was given only during reperfusion. A: Effect of Akt inhibition (API-2) on DAF-2 fluorescence in GSPE-treated cells. Similar to Figure 2A, DAF-2 fluorescence was increased during reperfusion, and further augmented by addition of GSPE. API-2 partially reversed the GSPE-induced increase in DAF-2 fluorescence at reperfusion ( $P < 0.05$ ), while API-2 alone did not affect the DAF-2 fluorescence in the I/R control. B: Effect of Akt inhibition on GSPE-induced protection. API-2 partially abrogated the GSPE-induced protection. # $P < 0.01$  versus GSPE-treated cells.




Fig. 4. Effect of I/R and GSPE treatment on Akt phosphorylation. A: Cardiomyocytes were subjected to experimental conditions, and cytosolic extracts were prepared from cells in the presence or absence of GSPE and API-2. GSPE (50  $\mu\text{g/ml}$ ) was given during reperfusion and API-2 (10  $\mu\text{M}$ ) was pretreated for 1 h and through I/R. The phosphorylation of Akt at Ser473 was analyzed by Western blot. Ischemia alone resulted in a decrease of phospho-Akt with a slight increase in phospho-Akt following 30 min reperfusion. GSPE caused a significant increase in phospho-Akt during reperfusion as compared to ischemia only or 30 min standard reperfusion. The GSPE-induced elevated phospho-Akt level was blocked by the addition of the API-2. Western blot shown is representative of three independent experiments. B: Densitometric analysis of Akt phosphorylation in GSPE-treated cells. Densitometric analysis of Western blots was carried out using Quantity One Software (Bio-Rad, Richmond, CA). Densitometric results are presented as the ratio of phospho-Akt/total Akt. Values are means  $\pm$  SEM of three independent experiments. GSPE-induced a significant increase in phospho-Akt (<sup>#</sup> $P < 0.01$ ) during reperfusion, which was significantly attenuated by API-2 (<sup>\*</sup> $P < 0.001$ ).

increased phospho-Akt induced by GSPE ( $P < 0.001$ ). These results support a role for phospho-Akt in GSPE-mediated cardioprotection in this model.

#### GSPE-INDUCED NO PRODUCTION VIA AN Akt-eNOS PATHWAY

Because inhibition of either Akt or NOS resulted in only a partial blockade of protective NO generation, we examined whether the activation of Akt and eNOS could be acting in the same or separate pathways. For these studies, cells were treated concurrently with L-NAME (200  $\mu\text{M}$ ) and API-2 (10  $\mu\text{M}$ ) following the above protocols. As shown in Figure 5, as with either inhibitor alone, a partial inhibition of GSPE-induced NO generation was seen [ $1,404 \pm 96$  a.u. GSPE + API-2 + L-NAME ( $n = 5$ ) vs.  $1,812 \pm 51$  a.u. GSPE alone ( $n = 5$ ) at 2 h reperfusion,  $P < 0.05$ ]. These results suggest that Akt may be important in the activation of eNOS-mediated NO production, which leads to GSPE-induced protection. Overall, these results indicate that GSPE may induce NO through a mechanism involving the activation of an Akt-eNOS pathway.

#### DISCUSSION

In the current study, we demonstrate that acute treatment with grape seed proanthocyanidin extract (GSPE) significantly reduces cardiomyocyte death and leads to the return of spontaneous contractions in our model of ischemia and reperfusion (I/R) injury. The protective effect of GSPE was associated with an enhanced, sustained NO generation at reperfusion that was abrogated by NOS inhibition. GSPE given during reperfusion also increased phosphorylation of the survival kinase Akt at Ser473 following I/R while inhibition of Akt by API-2 decreased phospho-Akt levels and the GSPE-induced protection. These results suggest that GSPE protects cardiomyocytes from I/R injury, at least in part, by increasing Akt




Fig. 5. Effect of NOS and Akt inhibition on NO production. Cells were pretreated with both API-2 (10  $\mu\text{M}$ ) and L-NAME (200  $\mu\text{M}$ ) as previously described; GSPE was given at reperfusion only. Concurrent treatment with both inhibitors partially inhibited the augmented DAF-2 fluorescence induced by GSPE. Data are expressed as means  $\pm$  SEM. <sup>†</sup> $P < 0.05$  versus GSPE-treated cells.

phosphorylation, which leads to the maintenance of an elevated level of NO.

NO has been implicated as a cardioprotective agent during I/R injury in various cell types and models [Gao et al., 2002; Brunner et al., 2003; Li et al., 2008] and its release in reperfused tissues has been attributed to the activation of NOS, especially eNOS [Bolli, 2001; Schulz et al., 2004]. In one study, primary cardiomyocytes and murine embryonic fibroblasts were protected against I/R induced cell death when physiological levels of NO (1% in N<sub>2</sub>) were given exogenously during ischemia [Iwase et al., 2007]. Furthermore, a NO donor given throughout I/R has also been shown to be protective in a mouse heart Langendorff model [Bell et al., 2003]. In an in vivo rat model, a statin given just prior to reperfusion exerted an acute protective effect against myocardial reperfusion injury by increasing the phosphorylation of eNOS via the PI3-K/Akt pathway [Wolfrum et al., 2004]. In the current study, we extend our prior work that showed GSPE stimulated a concentration-dependent NO production in untreated cardiomyocytes [Shao et al., 2006] by investigating whether GSPE-induced NO generation at reperfusion was protective in our cardiomyocyte model and examined the potential mechanism behind this protection.

Our studies show that NO increases in non-GSPE treated cardiomyocytes at reperfusion, corroborating the results reported in other studies [Bolli, 2001; Schulz et al., 2004]. We also find that GSPE given during reperfusion results in an enhanced, sustained NO level that is significantly higher than that of the control I/R group (Fig. 2A). These results suggest that GSPE stimulates an augmented NO response and that this response is generated through a NOS isoform (i.e., an enzyme-dependent mechanism) since L-NAME inhibits it. Furthermore, we find that the protective effect of GSPE during I/R is dependent on this increased NO release as NOS inhibition with L-NAME eliminates the protective effect of GSPE. Taken together, these results suggest that GSPE induces an enzyme-dependent NO production in reperfused cardiomyocytes.

The exact mechanism by which NO exerts its protective effects in the context of I/R has not been completely elucidated. NO may act by reducing intracellular calcium concentration and thereby reducing cell death [Mery et al., 1993] or it may act by reducing myocardial contractility and myocardial oxygen consumption that results in attenuated mitochondrial ROS formation [Xie et al., 1998; Scott et al., 2001]. NO may also mediate mitochondrial K<sub>ATP</sub> channel opening, which has been associated with reduced reperfusion injury [Sasaki et al., 2000]. NO also augments antioxidant protection by forming intracellular antioxidants (nitrosothiols and glutathione) [Ronson et al., 1999] and by reducing ROS release through inhibition of NADPH oxidase activity [Fujii et al., 1997]. In addition, eNOS over-expression induced in endothelial tissue improved reperfusion injury in a transgenic mouse model [Jones et al., 2004], underlining the fact that enzymatic NO attenuates reperfusion injury. Further studies elucidating how GSPE induced NO regulates I/R injury are ongoing.

The mechanism by which GSPE induces NO production in cardiomyocytes has not been elucidated in previous studies. However, GSPE has been shown to stimulate NO formation in various cell types such as endothelial and glial cells [Roychowdhury et al., 2001; Berti et al., 2003; Vitseva et al., 2005], and it had been

postulated that GSPE may induce NO formation by the redox-sensitive activation of Src kinase with the subsequent PI3-kinase/Akt-dependent phosphorylation of eNOS in the endothelium [Anselm et al., 2007]. Additional studies have shown that inhibiting Akt blocks GSPE-induced activation of eNOS in human umbilical vascular endothelial cells [Edirisinghe et al., 2008] and this mechanism was also shown to exist in adult rat cardiomyocytes [Xu et al., 2005]. Furthermore, polyphenolic compounds found in red wines have also been shown to induce protection via increased NO release, which is due to a PI3-K-dependent activation of Akt [Ndiaye et al., 2005]. PI3-K is a redox-sensitive kinase; thus, it may be activated through changes in intracellular ROS levels, leading to eNOS activation and increased NO release [Ndiaye et al., 2005]. In this study, we showed that GSPE's cardioprotective effects are associated with increased phospho-Akt signaling at Ser473 within 30 min of administration and that these effects are blocked with the Akt inhibitor API-2 (Fig. 4). API-2 also blocked GSPE increases in NO (Fig. 3A). These results suggest that the cardioprotective effect of GSPE may lie with its ability to induce NO production via Akt signaling. Thus, our results show that the increase in, or maintenance of, phospho-Akt is critical to GSPE-induced cardioprotection and that phospho-Akt is, in part, responsible for the activation of eNOS. In contrast to our work, a recent study by Engelbrecht et al. demonstrated that GSPE attenuated PI3 K/Akt phosphorylation in a colon cancer cell line (CaCo2) and enhanced apoptosis. However, this study did not show the effects of GSPE on Akt in normal terminally differentiated cells. Thus, GSPE may have divergent effects on Akt signaling depending on cell phenotype, but the mechanisms for this remain unknown [Engelbrecht et al., 2007].

In conclusion, GSPE conferred protection in our cardiomyocyte model of I/R which was associated with increases in NO and phospho-Akt. GSPE induced cardioprotection was abrogated in the presence of the NO inhibitor L-NAME and the Akt inhibitor API-2 suggesting that the Akt-NOS pathway is important for GSPE induced cardioprotection. We believe the increased NO concentration produced a cytoprotective environment, resulting in reduced cell death and restoration of contractile function following reperfusion. Thus, the protection conferred by GSPE against reperfusion injury appears to be mediated by increased NO production during reperfusion via the activation of Akt and an enzymatic isoform of NOS.

## ACKNOWLEDGMENTS

This work was supported, in part, by National Institutes of Health grants HL68951, HL65558, HL79641 HL084643, AT002176, AT003255, and AT01575. The authors thank Prof. J. Q. Cheng (H. Lee Moffitt Cancer Center & Research Institute, FL) for the generous gift of the Akt inhibitor. We also thank Michael Retzer for editing this manuscript.

## REFERENCES

Ambrosio G, Tritto I, Chiariello M. 1995. The role of oxygen free radicals in preconditioning. *J Mol Cell Cardiol* 27:1035-1039.

- Anselm E, Chataigneau M, Ndiaye M, Chataigneau T, Schini-Kerth VB. 2007. Grape juice causes endothelium-dependent relaxation via a redox-sensitive Src- and Akt-dependent activation of eNOS. *Cardiovasc Res* 73:404–413.
- Bagchi D, Sen CK, Ray SD, Das DK, Bagchi M, Preuss HG, Vinson JA. 2003. Molecular mechanisms of cardioprotection by a novel grape seed proanthocyanidin extract. *Mutat Res* 523–524:87–97.
- Bell RM, Maddock HL, Yellon DM. 2003. The cardioprotective and mitochondrial depolarising properties of exogenous nitric oxide in mouse heart. *Cardiovasc Res* 57:405–415.
- Berti F, Manfredi B, Mantegazza P, Rossoni G. 2003. Procyanidins from *Vitis vinifera* seeds display cardioprotection in an experimental model of ischemia-reperfusion damage. *Drugs Exp Clin Res* 29:207–216.
- Bolli R. 2001. Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: an overview of a decade of research. *J Mol Cell Cardiol* 33:1897–1918.
- Bolli R. 2007. Preconditioning: A paradigm shift in the biology of myocardial ischemia. *Am J Physiol Heart Circ Physiol* 292:H19–H27.
- Bradamante S, Barengli L, Piccinini F, Bertelli AA, De Jonge R, Beemster P, De Jong JW. 2003. Resveratrol provides late-phase cardioprotection by means of a nitric oxide- and adenosine-mediated mechanism. *Eur J Pharmacol* 465:115–123.
- Brunner F, Maier R, Andrew P, Wolkart G, Zechner R, Mayer B. 2003. Attenuation of myocardial ischemia/reperfusion injury in mice with myocyte-specific overexpression of endothelial nitric oxide synthase. *Cardiovasc Res* 57:55–62.
- Chang WT, Shao ZH, Yin JJ, Mehendale S, Wang CZ, Qin Y, Li J, Chen WJ, Chien CT, Becker LB, Vanden Hoek TL, Yuan CS. 2007. Comparative effects of flavonoids on oxidant scavenging and ischemia-reperfusion injury in cardiomyocytes. *Eur J Pharmacol* 566:58–66.
- Das DK, Maulik N. 2006. Resveratrol in cardioprotection: A therapeutic promise of alternative medicine. *Mol Interv* 6:36–47.
- Edirisinghe I, Burton-Freeman B, Tissa Kappagoda C. 2008. The mechanism of the endothelium dependent relaxation evoked by a grape seed extract. *Clin Sci* 114(4): 331–337.
- Engelbrecht AM, Mattheyse M, Ellis B, Loos B, Thomas M, Smith R, Peter S, Smith C, Myburgh K. 2007. Proanthocyanidin from grape seeds inactivates the PI3-kinase/PKB pathway and induces apoptosis in a colon cancer line. *Cancer Lett* 258:144–153.
- Fujii H, Ichimori K, Hoshiai K, Nakazawa H. 1997. Nitric oxide inactivates NADPH oxidase in pig neutrophils by inhibiting its assembling process. *J Biol Chem* 272:32773–32778.
- Gao F, Gao E, Yue TL, Ohlstein EH, Lopez BL, Christopher TA, Ma XL. 2002. Nitric oxide mediates the antiapoptotic effect of insulin in myocardial ischemia-reperfusion: The roles of PI3-kinase, Akt, and endothelial nitric oxide synthase phosphorylation. *Circulation* 105:1497–1502.
- Goh SS, Woodman OL, Pepe S, Cao AH, Qin C, Ritchie RH. 2007. The red wine antioxidant resveratrol prevents cardiomyocyte injury following ischemia-reperfusion via multiple sites and mechanisms. *Antioxid Redox Signal* 9:101–113.
- Ha T, Hua F, Liu X, Ma J, McMullen JR, Shioi T, Izumo S, Kelley J, Gao X, Browder W, Williams DL, Kao RL, Li C. 2008. Lipopolysaccharide-induced myocardial protection against ischaemia/reperfusion injury is mediated through a PI3K/Akt-dependent mechanism. *Cardiovasc Res* 78:546–553.
- Hattori R, Otani H, Maulik N, Das DK. 2002. Pharmacological preconditioning with resveratrol: Role of nitric oxide. *Am J Physiol Heart Circ Physiol* 282:H1988–H1995.
- Hung LM, Chen JK, Huang SS, Lee RS, Su MJ. 2000. Cardioprotective effect of resveratrol, a natural antioxidant derived from grapes. *Cardiovasc Res* 47: 549–555.
- Iwase H, Robin E, Guzy RD, Mungai PT, Vanden Hoek TL, Chandel NS, Levraut J, Schumacker PT. 2007. Nitric oxide during ischemia attenuates oxidant stress and cell death during ischemia and reperfusion in cardiomyocytes. *Free Radic Biol Med* 43:590–599.
- Jones SP, Bolli R. 2006. The ubiquitous role of nitric oxide in cardioprotection. *J Mol Cell Cardiol* 40:16–23.
- Jones SP, Greer JJ, Kakkar AK, Ware PD, Turnage RH, Hicks M, van Haperen R, de Crom R, Kawashima S, Yokoyama M, Lefer DJ. 2004. Endothelial nitric oxide synthase overexpression attenuates myocardial reperfusion injury. *Am J Physiol Heart Circ Physiol* 286:H276–H282.
- Karthikeyan K, Bai BR, Devaraj SN. 2007. Cardioprotective effect of grape seed proanthocyanidins on isoproterenol-induced myocardial injury in rats. *Int J Cardiol* 115:326–333.
- Kojima H, Nakatsubo N, Kikuchi K, Kawahara S, Kirino Y, Nagoshi H, Hirata Y, Nagano T. 1998. Detection and imaging of nitric oxide with novel fluorescent indicators: Diaminofluoresceins. *Anal Chem* 70:2446–2453.
- Lebuffe G, Schumacker PT, Shao ZH, Anderson T, Iwase H, Vanden Hoek TL. 2003. ROS and NO trigger early preconditioning: Relationship to mitochondrial KATP channel. *Am J Physiol Heart Circ Physiol* 284:H299–H308.
- Li J, Zhang H, Wu F, Nan Y, Ma H, Guo W, Wang H, Ren J, Das UN, Gao F. 2008. Insulin inhibits tumor necrosis factor- $\alpha$  induction in myocardial ischemia/reperfusion: Role of Akt and endothelial nitric oxide synthase phosphorylation. *Crit Care Med* 36:1551–1558.
- Mery PF, Pavoine C, Belhassen L, Pecker F, Fischmeister R. 1993. Nitric oxide regulates cardiac Ca<sup>2+</sup> current. Involvement of cGMP-inhibited and cGMP-stimulated phosphodiesterases through guanylyl cyclase activation. *J Biol Chem* 268:26286–26295.
- Ndiaye M, Chataigneau M, Lobysheva I, Chataigneau T, Schini-Kerth VB. 2005. Red wine polyphenol-induced, endothelium-dependent NO-mediated relaxation is due to the redox-sensitive PI3-kinase/Akt-dependent phosphorylation of endothelial NO-synthase in the isolated porcine coronary artery. *FASEB J* 19:455–457.
- Rice-Evans C. 2001. Flavonoid antioxidants. *Curr Med Chem* 8:797–807.
- Rice-Evans C. 2004. Flavonoids and isoflavones: Absorption, metabolism, and bioactivity. *Free Radic Biol Med* 36:827–828.
- Ronson RS, Nakamura M, Vinten-Johansen J. 1999. The cardiovascular effects and implications of peroxynitrite. *Cardiovasc Res* 44:47–59.
- Roviezzo F, Cuzzocrea S, Di Lorenzo A, Brancalione V, Mazzon E, Di Paola R, Bucci M, Cirino G. 2007. Protective role of PI3-kinase-Akt-eNOS signalling pathway in intestinal injury associated with splanchnic artery occlusion shock. *Br J Pharmacol* 151:377–383.
- Roychowdhury S, Wolf G, Keilhoff G, Bagchi D, Horn T. 2001. Protection of primary glial cells by grape seed proanthocyanidin extract against nitrosative/oxidative stress. *Nitric Oxide* 5:137–149.
- Sasaki N, Sato T, Ohler A, O'Rourke B, Marban E. 2000. Activation of mitochondrial ATP-dependent potassium channels by nitric oxide. *Circulation* 101:439–445.
- Sato M, Maulik G, Ray PS, Bagchi D, Das DK. 1999. Cardioprotective effects of grape seed proanthocyanidin against ischemic reperfusion injury. *J Mol Cell Cardiol* 31:1289–1297.
- Schulz R, Kelm M, Heusch G. 2004. Nitric oxide in myocardial ischemia/reperfusion injury. *Cardiovasc Res* 61:402–413.
- Scott GI, Colligan PB, Ren BH, Ren J. 2001. Ginsenosides Rb1 and Re decrease cardiac contraction in adult rat ventricular myocytes: Role of nitric oxide. *Br J Pharmacol* 134:1159–1165.
- Shao ZH, Becker LB, Vanden Hoek TL, Schumacker PT, Li CQ, Zhao D, Wojcik K, Anderson T, Qin Y, Dey L, Yuan CS. 2003. Grape seed proanthocyanidin extract attenuates oxidant injury in cardiomyocytes. *Pharmacol Res* 47:463–469.
- Shao ZH, Hsu CW, Chang WT, Waypa GB, Li J, Li D, Li CQ, Anderson T, Qin Y, Schumacker PT, Becker LB, Hoek TL. 2006. Cytotoxicity induced by grape seed proanthocyanidins: Role of nitric oxide. *Cell Biol Toxicol* 22:149–158.



- Thirunavukkarasu M, Penumathsa SV, Koneru S, Juhasz B, Zhan L, Otani H, Bagchi D, Das DK, Maulik N. 2007. Resveratrol alleviates cardiac dysfunction in streptozotocin-induced diabetes: Role of nitric oxide, thioredoxin, and heme oxygenase. *Free Radic Biol Med* 43:720–729.
- Toth A, Halmosi R, Kovacs K, Deres P, Kalai T, Hideg K, Toth K, Sumegi B. 2003. Akt activation induced by an antioxidant compound during ischemia-reperfusion. *Free Radic Biol Med* 35:1051–1063.
- Vanden Hoek TL, Shao Z, Li C, Zak R, Schumacker PT, Becker LB. 1996. Reperfusion injury on cardiac myocytes after simulated ischemia. *Am J Physiol* 270:H1334–H1341.
- Vanden Hoek, TL, Shao Z, Li C, Schumacker PT, Becker LB. 1997. Mitochondrial electron transport can become a significant source of oxidative injury in cardiomyocytes. *J Mol Cell Cardiol* 29:2441–2450.
- Vitseva O, Varghese S, Chakrabarti S, Folts JD, Freedman JE. 2005. Grape seed and skin extracts inhibit platelet function and release of reactive oxygen intermediates. *J Cardiovasc Pharmacol* 46:445–451.
- Wallerath T, Deckert G, Ternes T, Anderson H, Li H, Witte K, Forstermann U. 2002. Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. *Circulation* 106:1652–1658.
- Wolfrum S, Dendorfer A, Schutt M, Weidtmann B, Heep A, Tempel K, Klein HH, Dominiak P, Richardt G. 2004. Simvastatin acutely reduces myocardial reperfusion injury in vivo by activating the phosphatidylinositol 3-kinase/Akt pathway. *J Cardiovasc Pharmacol* 44:348–355.
- Xie YW, Kaminski PM, Wolin MS. 1998. Inhibition of rat cardiac muscle contraction and mitochondrial respiration by endogenous peroxynitrite formation during posthypoxic reoxygenation. *Circ Res* 82:891–897.
- Xu Z, Park SS, Mueller RA, Bagnell RC, Patterson C, Boysen PG. 2005. Adenosine produces nitric oxide and prevents mitochondrial oxidant damage in rat cardiomyocytes. *Cardiovasc Res* 65:803–812.
- Zweier JL, Talukder MA. 2006. The role of oxidants and free radicals in reperfusion injury. *Cardiovasc Res* 70:181–190.